Navigation Links
Amgen Announces Evolocumab (AMG 145) Results From First 52-Week Study Of A PCSK9 Inhibitor To Reduce LDL Cholesterol
Date:11/19/2013

ns and reimbursement policies may affect the development, usage and pricing of our products. In addition, we compete with other companies with respect to some of our marketed products as well as for the discovery and development of new products. We believe that some of our newer products, product candidates or new indications for existing products, may face competition when and as they are approved and marketed. Our products may compete against products that have lower prices, established reimbursement, superior performance, are easier to administer, or that are otherwise competitive with our products. In addition, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors and there can be no guarantee of our ability to obtain or maintain patent protection for our products or product candidates. We cannot guarantee that we will be able to produce commercially successful products or maintain the commercial success of our existing products. Our stock price may be affected by actual or perceived market opportunity, competitive position, and success or failure of our products or product candidates. Further, the discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations.

The scientific information discussed in this news release related to our product candidates is preliminary and investigative. Such product candidates are not approved by the U.S. Food and Drug Administration (FDA), and no conclusions can or should be drawn regarding the safety or effectiveness of the product candidates.

CONTACT: Amgen
Ashleigh Koss: 805-313-6151 (media)
Arvind Sood: 805-447-1060 (investors)

'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Amgen Presents Interim Overall Survival Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
2. Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
3. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
4. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
5. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
6. Amgen And Servier Complete Product Collaboration Transaction
7. Amgen Announces 2013 Third Quarter Dividend
8. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
9. Amgen And Servier Announce Product Collaboration
10. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
11. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... EvoDerma ’s NOOME Anti-Aging Motion has been upgraded ... with a second treatment cup to help prevent and smooth ... is thinner on the edges for a softer contact with ... uneven surfaces on the face, neck and décolleté. Choose to ... areas such as the cheeks and neck, or opt for ...
(Date:7/10/2014)... POINT, Ind. , July 10, 2014 ... expanded its use of capnography for respiratory ... growing group of healthcare leaders in embracing ... measures how effectively patients are breathing and ... depression occurs. By measuring the amount of ...
(Date:7/10/2014)... -- Kainos Capital, a firm specializing in acquiring and managing ... acquired the Slim-Fast brand from Unilever. Unilever will retain ... transaction were not disclosed. Slim-Fast is a ... ready-to-drink shakes, powders, bars and snacks to retail customers ... the United Kingdom and Ireland.  ...
(Date:7/10/2014)... , July 10, 2014 Research ... addition of the "International Photonic Integrated Circuit ... Forecasts to 2019" report to their offering. ... The concept of photonic integration traces its ... century. The promise of photonic integration went unexplored ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2Kainos Capital Acquires Slim-Fast From Unilever 2International Photonic Integrated Circuit (Monolithic Integration, Hybrid Integration, Module Integration) Market - Forecasts to 2019 2
... and chief executive officer with Radiation Shield Technologies (RST), ... the Radiological Society of North America (RSNA) 94th Scientific ... a.m. to 5 p.m. Nov. 30 to Dec. 5 ... Dr., Chicago. North Building, Hall B. Booth No.: 9517. ...
... DNA Mini Portrait™ is this years, most unique must-have gift , ... ... of custom portraits made from the customers, DNA, launch DNA Mini Portraits™, ... and pop culture. DNA Minis are the most personal and unique ...
... Calif., and SEATTLE, Nov. 26 Spectrum,Pharmaceuticals, Inc. ... Inc.,(Nasdaq: CTIC )(MTA: CTIC) announced today ... 50/50 owned joint venture, RIT Oncology LLC, to ... States.,ZEVALIN, a radioimmunotherapeutic (RIT), is currently marketed in ...
Cached Biology Technology: New Radiation-Blocking Medical Garments Introduced at RSNA Meeting in Chicago : Demron-M Technology Provides Total Protection in a Lightweight, Durable, Flexible Fabric 2DNA 11, Creators of DNA Art, Introduces a More Affordable Line of Custom Portraits for this Year's Gift Giving Season 2Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 2Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 3Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 4Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 5Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 6Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 7Spectrum Pharmaceuticals and Cell Therapeutics to Jointly Market ZEVALIN, a Proprietary, Marketed Oncology Drug 8
(Date:7/10/2014)... -- Fingerprint Cards, (FPC,s) new mobile touch sensor ... Chinese Top 5 smartphone OEM has selected FPC1021 for a ... October 2014.   FPC is proud to announce ... has a planned date for the start of mass production ... phone of 3 million units. The Chinese OEM wants to ...
(Date:7/10/2014)... , July 9, 2014  Acuity Market Intelligence today released ... 2014 Edition" indicating that the global market for National Electronic ... 2013 to 2018. During this time, the number of National ... 3.5 billion. Asia , with its vast ... National eID cards issued, while Europe ...
(Date:7/10/2014)... for Basic Science (IBS), the main organization of the ... has announced that a group of researchers, led by ... in the field of optogenetics that can remotely control ... technology "OptoTrk" and it has succeeded with neuronal differentiation ... is that it requires only light to activate neuronal ...
Breaking Biology News(10 mins):FPC Wins DW for 1021 Touch Sensor for Flagship Smartphone from Chinese Top 5 Smartphone OEM 2National Electronic ID Programs Generate $54 Billion Between 2013 and 2018 with 3.5 Billion National eID Card Holders Worldwide 2New optogenetic tool for controlling neuronal signalling by blue light 2
... N.M. A matchbook-sized atomic clock 100 times smaller than ... researchers at Symmetricom Inc. Draper Laboratory and Sandia National Laboratories. ... 1.5 inches on a side and less than a half-inch ... its predecessors. Instead of 10 watts, it uses only 100 ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... today announced that Edmund C. Reiter has resigned, effective April ... of the board of the company citing personal reasons.   ... General Counsel have been named co-CEOs and co-Presidents on an ...
... April 11, 2011 MiMedx Group, Inc. (OTCBB: MDXG), ... biomaterial-based products and bioimplants processed from human amniotic membrane, ... product, EpiFix™, a biologic implant specifically processed to offer ... options. The Company also announces the hiring of Frank ...
Cached Biology News:World's smallest atomic clock on sale 2World's smallest atomic clock on sale 3World's smallest atomic clock on sale 4Aware, Inc. Announces Resignation of Chief Executive Officer 2Aware, Inc. Announces Resignation of Chief Executive Officer 3MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 2MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 3MiMedx Group Announces Launch of EpiFix™ and Hiring of Vice President, Wound Care 4
... GC-rich nucleic acids ,The GC-RICH PCR ... and a proofreading polymerase, powers through templates ... with other polymerases and other blends of ... and the unique GC-RICH Resolution Solution combine ...
... Hot Start Taq ... activity before the onset ... nonspecific amplification and primer-dimer ... is raised, the antibody ...
B-FABP (FL-132)...
Roll of Mesh 5m x 25cm...
Biology Products: